By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Pharmacyclics, Inc. 

995 East Arques Avenue

Sunnyvale  California  94086  U.S.A.
Phone: 408-774-0330 Fax: 408-774-0340


Company News
Ariad (ARIA) Taps Former Pharmacyclics (PCYC) Exec as New CFO 3/11/2016 5:49:16 AM
Cancer Stem Cells: Genoscience Pharma Welcomes Pharmacyclics (PCYC) Founders To Its Board Of Directors 2/24/2016 9:51:17 AM
Led By a Team of Ex-Pharmacyclics (PCYC) Execs, Corvus Pharma Eyes $115 Million IPO 1/5/2016 6:42:52 AM
Pharmacyclics (PCYC)' "Miracle Cure": A Cancer Drug 12/30/2015 7:07:39 AM
Ex-Pharmacyclics (PCYC) CEO Banks $33.5 Million for Startup Corvus Pharma 7/6/2015 6:22:23 AM
Pharmacyclics (PCYC) Release: Ibrutinib (IMBRUVICA) Improved Survival For Treatment-Naive Chronic Lymphocytic Leukemia Patients In Phase III RESONATE-2 Trial 6/4/2015 7:28:29 AM
Pharmacyclics (PCYC) Release: Phase III HELIOS Study Results Show Ibrutinib (IMBRUVICA) Combination Therapy Significantly Increased Progression-Free Survival In Previously-Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Patients 6/1/2015 6:27:26 AM
Pharmacyclics (PCYC) Release: Analysis Of Phase III RESONATE Data Shows Adherence To The Recommended 420mg Dose Of IMBRUVICA (Ibrutinib) Results In Improved Efficacy Benefits In Patients With Chronic Lymphocytic Leukemia 6/1/2015 6:16:50 AM
Pharmacyclics (PCYC) Release: Ibrutinib (IMBRUVICA) Phase Ib/II Data Show Promise In Patients With Chronic Graft-Versus-Host-Disease 6/1/2015 6:12:15 AM
Pharmacyclics (PCYC) Release: Ibrutinib (IMBRUVICA) In Combination With Anti-PD-L1 Antibody (MEDI4736) Study Commences For Patients With Two Relapsed/Refractory Blood Cancers 5/28/2015 7:26:28 AM